Baron Y M, Brincat M P, Galea R
Department of Obstetrics and Gynecology, St. Luke's Hospital, Gwardamangia, Malta.
Climacteric. 1999 Sep;2(3):189-96. doi: 10.3109/13697139909038061.
Long-term corticosteroid therapy is complicated by osteoporosis and generalized thinning of the skin. These two complications of such therapy were routinely assessed at the Menopause Clinic of St. Luke's Hospital Medical School, University of Malta.
A cross-sectional study was performed on 64 postmenopausal women who had been taking long-term corticosteroids. Each woman had her skin thickness measured using high-resolution ultrasound (22 MHz) and her bone density measured by dual-energy X-ray absorptiometry (DEXA). These measurements were compared with those of a control group (n = 557), a group of women who had sustained osteoporotic fractures (n = 180) and a group of women taking hormone replacement therapy (HRT) (n = 399). A longitudinal study of 29 postmenopausal women taking corticosteroids was also performed. This study compared results for women who, in addition to their corticosteroids, were taking HRT and for those who were taking corticosteroids alone.
The cross-sectional study showed that corticosteroid therapy was associated with the lowest mean skin thickness measurement (0.83 mm). Similarly, low mean bone density measurements for the lumbar spine (0.805 g/cm2) and left hip (0.715 g/cm2) were obtained for this group. The mean skin thicknesses in the control group and the HRT group were 0.93 mm and 0.935 mm, respectively, while that in the osteoporotic fracture group was 0.88 mm. The bone density of the fracture group was similar to that of the group of women taking long-term corticosteroids, with the lumbar spine having a mean density of 0.805 g/cm2 and 0.81 g/cm2, and the left hip having a density of 0.705 g/cm2 and 0.715 g/cm2, respectively. Bone densities were similar for the control group and the HRT group, and higher than that of the corticosteroid or fracture group. The lumbar spine had a mean density of 0.925 g/cm2 in the control group and 0.93 g/cm2 in the hormonally treated group. Both the treated and control groups had similar bone densities of the left hip at about 0.82 g/cm2. The small longitudinal study compared postmenopausal women on long-term corticosteroid therapy taking HRT with another group who were not taking HRT. This 4-year study revealed mean total increases in skin thickness of 6.1% and bone density of 5.5% (left hip) and 14.6% (lumbar spine) in the HRT group, since the start of the study. Conversely, the control group registered reductions over 4 years in both skin thickness (2.8%) and bone density (lumbar spine 4.5% and hip 5.0%).
In postmenopausal women taking long-term corticosteroids, skin thickness and bone density were both decreased, but the addition of HRT as add-back improved the situation dramatically. Skin thickness and bone density in women taking long-term corticosteroids were comparable to those in women who had sustained osteoporotic fractures. It is therefore suggested that HRT be used as add-back therapy in postmenopausal women taking long-term corticosteroid therapy.
长期使用皮质类固醇治疗会并发骨质疏松症和皮肤普遍变薄。马耳他大学圣卢克医院医学院更年期诊所会定期评估这种治疗的这两种并发症。
对64名长期服用皮质类固醇的绝经后妇女进行了一项横断面研究。使用高分辨率超声(22兆赫)测量每位女性的皮肤厚度,并通过双能X线吸收法(DEXA)测量其骨密度。将这些测量结果与对照组(n = 557)、一组发生骨质疏松性骨折的女性(n = 180)和一组接受激素替代疗法(HRT)的女性(n = 399)的测量结果进行比较。还对29名服用皮质类固醇的绝经后妇女进行了一项纵向研究。该研究比较了除服用皮质类固醇外还服用HRT的女性和仅服用皮质类固醇的女性的结果。
横断面研究表明,皮质类固醇治疗与最低的平均皮肤厚度测量值(0.83毫米)相关。同样,该组腰椎(0.805克/平方厘米)和左髋部(0.715克/平方厘米)的平均骨密度测量值较低。对照组和HRT组的平均皮肤厚度分别为0.93毫米和0.935毫米,而骨质疏松性骨折组为0.88毫米。骨折组的骨密度与长期服用皮质类固醇的女性组相似,腰椎平均密度分别为0.805克/平方厘米和0.81克/平方厘米,左髋部密度分别为0.705克/平方厘米和0.715克/平方厘米。对照组和HRT组的骨密度相似,且高于皮质类固醇组或骨折组。对照组腰椎平均密度为0.925克/平方厘米,激素治疗组为0.93克/平方厘米。治疗组和对照组左髋部的骨密度相似,约为0.82克/平方厘米。这项小型纵向研究比较了长期接受皮质类固醇治疗并服用HRT的绝经后妇女与另一组未服用HRT的妇女。这项为期4年的研究显示,自研究开始以来,HRT组的皮肤厚度平均总增加了6.1%,骨密度(左髋部)增加了5.5%,(腰椎)增加了14.6%。相反,对照组在4年中皮肤厚度(2.8%)和骨密度(腰椎4.5%,髋部5.0%)均有所下降。
在长期服用皮质类固醇的绝经后妇女中,皮肤厚度和骨密度均降低,但添加HRT作为补充治疗可显著改善这种情况。长期服用皮质类固醇的女性的皮肤厚度和骨密度与发生骨质疏松性骨折的女性相当。因此,建议在长期接受皮质类固醇治疗的绝经后妇女中使用HRT作为补充治疗。